Portfolio Lab

UNITED THERAPEUTICS Corp

  • Stock
  • Ticker UTHR
  • ISIN US91307C1027
  • Nasdaq

Health care · Pharmaceuticals · USA

$554.73 −0.78%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of UNITED THERAPEUTICS Corp since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

UTHRGlobal equities (VT)

$10,000 grew to $42,201. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −55.6% in 07/2019, measured from the peak in 02/2017. It took 47 months to get back to the old peak.

1-year return
+16.9%
5-year return p.a.
+22.5%
10-year return p.a.
+15.5%
Volatility p.a.
34.0%
Largest decline
−55.6%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue736794799800790782783833
Gross profit660702711699687648684733
Operating income358383365389357326331308
EBITDA377403386410380348355334
Net income301322310339364275333259
Earnings per share6.216.636.417.167.695.827.275.71
Balance sheet
Total assets7,3647,7447,9087,3517,8806,7147,2207,034
Liabilities920937734761784813820758
Equity6,4446,8077,1746,5907,0965,9016,4006,276
Cash1,6971,9001,5931,3401,5571,2801,8031,189
Cash flow
Operating cash flow341461192562346463314307
Capital expenditure-87-75-62-211-173-101-108-181
Free cash flow255386130352173363206126

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +72.3%, weakest 2018 at −26.4%. 6 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
4 Nov 2026$5.71
5 Aug 2026$7.27
6 May 2026$5.82
25 Feb 2026$7.69
29 Oct 2025$7.16
30 Jul 2025$6.41
30 Apr 2025$6.63
26 Feb 2025$6.21
30 Oct 2024$6.39
31 Jul 2024$5.85
1 May 2024$6.17
21 Feb 2024$4.33

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€21bn
Market cap in trading currency
$23.6bn
Enterprise value
$21.6bn
P/E
20.9
P/S
7.41
P/B
3.76
EV/Sales
6.76
EV/EBITDA
15.2
Earnings yield
4.8%
FCF yield
3.7%

Results (last four quarters)

Revenue
$3.19bn
Gross profit
$2.75bn
EBITDA
$1.42bn
Net income
$1.23bn
Earnings per share
$26.49
Revenue per share
$74.84
Revenue growth
+4.1%
Earnings growth
−23.6%

Profitability

Gross margin
86.3%
Operating margin
41.4%
Net margin
38.6%
Return on equity
19.1%
Return on assets
17.5%

Balance sheet and cash flow

Cash
$2.07bn
Cash per share
$48.56
Financial debt
–
Debt/equity %
–
Current ratio
4.61
Book value per share
$147.36
Operating cash flow
$1.43bn
Free cash flow
$867m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
42.6m
Volume
355,142
Avg. volume 3 months
707,544
Relative volume
0.5

Price and technicals

Price
$554.73
1 day
−0.8%
52-week high
$608.49
52-week low
$464.93
Distance to 52-week high
−8.8%
Distance to 52-week low
+19.3%
Distance to 50-day line
+0.9%
Distance to 200-day line
+2.8%
RSI (14)
42
Volatility 1M
33.1%

Performance

1 week
−6.2%
1 month
−5.1%
3 months
+8.2%
6 months
−2.4%
YTD
+13.8%
1 year
+16.4%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has UTHR performed since 11/2016?

$10,000 grew to $42,201 by 20 Nov 2026, which is +15.5% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is UTHR?

Volatility was 34.0% per year, measured on monthly returns. The largest decline from a peak was −55.6%, with the low in 07/2019.

How does UTHR compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, UTHR returned +15.5% at 34.0%. The correlation of monthly returns was 0.25; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

UNITED THERAPEUTICS Corp (UTHR): Return and risk